Longitudinal real-world treatment and hospitalisation dynamics in relation to genetic liability across primary psychotic disorders and bipolar disorder
Using real-world data from the Estonian Biobank, this study demonstrates that while genetic liability influences healthcare contact patterns in primary psychotic and bipolar disorders, pharmacological treatment remains the strongest predictor of reduced rehospitalisation risk.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Imagine your brain as a complex, bustling city. Sometimes, the traffic lights in this city get a little glitchy, causing the whole system to spin out of control. This is what happens in severe mental health conditions like schizophrenia and bipolar disorder. For decades, scientists have known that these "glitches" are partly written in our DNA—like a blueprint that makes the city more prone to traffic jams. We also know that giving the city a steady supply of traffic controllers (medication) usually helps keep things moving. But here's the big question: Does the blueprint (your genes) tell us exactly how often the city will shut down, or does the traffic controller (the treatment) do the heavy lifting?
To answer this, researchers often run strict, controlled experiments, but those are like testing a car on a perfect, empty racetrack. Real life is messier. That's why scientists are turning to "real-world" data—massive digital records of how millions of people actually live, get sick, and get treated. By combining these medical records with DNA data, they can watch the "city" over many years to see what really keeps the traffic flowing. It's like having a time machine that lets us see if the blueprint or the traffic controller is the real hero in keeping the city from crashing.
The Great DNA vs. Medicine Showdown
A team of researchers in Estonia decided to play detective with a massive dataset called the Estonian Biobank. They gathered information on 1,625 people who had been diagnosed with primary psychotic disorders (like schizophrenia) or bipolar disorder. They didn't just look at a snapshot; they watched these individuals for a median of 11.3 years, tracking every time they visited a doctor, every time they were admitted to a hospital, and every time they picked up a prescription.
First, they wanted to make sure their "detective work" was solid. They checked if the people they identified actually had the genetic fingerprints of these disorders. They compared the DNA of their group against huge global studies and found a match that was almost perfect (a genetic correlation of over 0.88). This confirmed that their real-world data was a trustworthy map of the territory.
The Blueprint vs. The Traffic Controller
The team then asked: "Who is the boss here? Is it the genes, or is it the medicine?"
They looked at three things: how many times people visited the doctor, how many times they ended up in the hospital, and how long they stayed there.
- The Gene Clue: The researchers found that people with a higher "genetic load" (a score showing how much their DNA suggests they are at risk) did visit doctors more often. It's as if the blueprint made the city's residents more likely to call for help or check in with the traffic police. When it came to the very first major crash—being sent to the hospital for the first time after an initial admission—the genes did play a role; higher genetic risk was linked to a higher chance of that first rehospitalization. However, once someone was already in the system and facing repeated cycles of illness, the genes didn't seem to be the main driver of subsequent crashes.
- The Medicine Clue: This is where the story gets exciting. The researchers tracked exactly when people were taking their medication (antipsychotics and mood stabilizers) by looking at their prescription pickup records. They built a timeline showing when people were "ON" treatment and "OFF" treatment.
The results were clear: Medication was the hero. When people were taking their meds, their risk of being re-hospitalized dropped significantly. Specifically, the study found that being on treatment was associated with a 25% lower hazard of being sent back to the hospital for a second or third time. While genes helped predict that first return to the hospital, consistent treatment remained the strongest shield against repeated hospital stays.
The Verdict
The study suggests that while your DNA might make you more likely to need to see a doctor in the first place, and even influence that first return to the hospital, it doesn't necessarily doom you to a life of repeated hospital stays. Instead, the most powerful tool for keeping someone out of the hospital is simply staying on their medication.
The researchers were careful to note that this wasn't a magic cure-all. They admitted that their data was reconstructed from prescription records, not direct observation of people swallowing pills, so there's a tiny chance of some guesswork. They also noted that as people got older, their risk of re-hospitalization actually went down, which is a hopeful sign. But the main takeaway is a strong, measured suggestion: in the real world, consistent treatment is the strongest shield against the recurring chaos of these disorders, far more so than the genetic blueprint itself.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.